This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, announced the publication of a study, “Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level,” in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insulin-treated type 2 diabetes, regardless of their C-peptide levels.
Health Technology Insights: MY DR NOW Opens New Clinic in Queen Creek
Of the 319 participants in the 2IQP trial, 254 were included in this specific analysis. Researchers categorized participants, all of whom had type 2 diabetes and were using a t:slim X2 insulin pump with Control-IQ+ AID technology, into a ‘high C-peptide’ group (N=195) and a ‘low C-peptide’ group (N=59) based on CMS criteria.
Participants in the AID group experienced a mean HbA1c decrease of 0.8% from baseline, which was significantly greater than the control group. This improvement was the same between the high and low C-peptide groups, demonstrating that the benefit of AID is present regardless of C-peptide levels. Unfortunately, CMS criteria currently require a low C-peptide level for insulin pump coverage, which excludes many people with type 2 diabetes from obtaining an AID system, even if they had already been benefiting from the technology prior to moving to Medicare.
Health Technology Insights: HOYA Launches VisuPro Lenses for Early Presbyopia Support
“The 2IQP trial demonstrated that AID provides benefits to adults with insulin-treated type 2 diabetes across a range of demographics and treatment regimens, comparable to the outcomes seen in type 1 diabetes,” said Irl B. Hirsch, MD, from the University of Washington School of Medicine and lead author of the manuscript. “These new analyses show that AID is effective regardless of C-peptide levels, indicating that a low C-peptide threshold should not be required for therapy.”
Health Technology Insights: University Lab Partners and BARDA Launches ReadyDetect: A $10 Million Competition For Diagnostics
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
